{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:27:30Z","timestamp":1791214050602,"version":"4.1.0"},"reference-count":98,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.cyto.2014.11.026","type":"journal-article","created":{"date-parts":[[2014,12,23]],"date-time":"2014-12-23T06:15:48Z","timestamp":1419315348000},"page":"319-325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["The role of type I interferons and other cytokines in dermatomyositis"],"prefix":"10.1016","volume":"73","author":[{"given":"Ashish","family":"Arshanapalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9740-8429","authenticated-orcid":false,"given":"Mihir","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0511-1418","authenticated-orcid":false,"given":"Vindhya","family":"Veerula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ally-Khan","family":"Somani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2014.11.026_b0005","series-title":"Dermatology","author":"Bolognia","year":"2012"},{"key":"10.1016\/j.cyto.2014.11.026_b0010","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0733-8635(02)00021-9","article-title":"Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects","volume":"20","author":"Sontheimer","year":"2002","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.cyto.2014.11.026_b0015","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1136\/ard.39.5.500","article-title":"Muscle biopsy in polymyositis and dermatomyositis: a clinicopathological study","volume":"39","author":"Schwarz","year":"1980","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cyto.2014.11.026_b0020","article-title":"Cancer risk in dermatomyositis: a systematic review of the literature","author":"Di Rollo","year":"2014","journal-title":"Giornale italiano di dermatologia e venereologia: organo ufficiale, Societa italiana di dermatologia e sifilografia"},{"key":"10.1016\/j.cyto.2014.11.026_b0025","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1055\/s-2008-1062267","article-title":"Inflammatory myopathies: evaluation and management","volume":"28","author":"Greenberg","year":"2008","journal-title":"Semin Neurol"},{"key":"10.1016\/j.cyto.2014.11.026_b0030","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1136\/pgmj.65.765.437","article-title":"Polymyositis-dermatomyositis: a clinical review","volume":"65","author":"Strauss","year":"1989","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.cyto.2014.11.026_b0035","first-page":"1140","article-title":"Dermatopolymyositis and other connective tissue diseases: a review of 105 cases","volume":"12","author":"Tymms","year":"1985","journal-title":"J Rheumatol"},{"key":"10.1016\/j.cyto.2014.11.026_b0040","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/art.1780271011","article-title":"Multiplicity of antibodies in myositis sera","volume":"27","author":"Reichlin","year":"1984","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cyto.2014.11.026_b0045","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1097\/00002281-200311000-00006","article-title":"Skin involvement in dermatomyositis","volume":"15","author":"Santmyire-Rosenberger","year":"2003","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.cyto.2014.11.026_b0050","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0889-857X(02)00030-3","article-title":"Muscle biopsy findings in inflammatory myopathies","volume":"28","author":"Dalakas","year":"2002","journal-title":"Rheumatic Diseases Clinics North America"},{"key":"10.1016\/j.cyto.2014.11.026_b0055","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1001\/archderm.139.8.1027","article-title":"The handheld dermatoscope as a nail-fold capillaroscopic instrument","volume":"139","author":"Bergman","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.cyto.2014.11.026_b0060","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0140-6736(68)90302-4","article-title":"Nail-fold capillaries in connective-tissue disorders","volume":"1","author":"Buchanan","year":"1968","journal-title":"Lancet"},{"key":"10.1016\/j.cyto.2014.11.026_b0065","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaad.2008.02.043","article-title":"The treatment and prognosis of dermatomyositis: an updated review","volume":"59","author":"Iorizzo","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.cyto.2014.11.026_b0070","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jaad.2013.06.007","article-title":"Intravenous immunoglobulin for refractory cutaneous dermatomyositis: a retrospective analysis from an academic medical center","volume":"69","author":"Femia","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.cyto.2014.11.026_b0075","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1001\/archderm.144.10.1341","article-title":"Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling","volume":"144","author":"Somani","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.cyto.2014.11.026_b0080","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1742-1241.2005.00651.x","article-title":"Interferon-induced sarcoidosis","volume":"60","author":"Alazemi","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.cyto.2014.11.026_b0085","first-page":"20","article-title":"Interferon: mechanisms of action and clinical value","volume":"2","author":"Houglum","year":"1983","journal-title":"Clin Pharm"},{"key":"10.1016\/j.cyto.2014.11.026_b0090","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nm1590","article-title":"TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity","volume":"13","author":"Baccala","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.cyto.2014.11.026_b0095","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev.immunol.23.021704.115843","article-title":"Type I interferons (alpha\/beta) in immunity and autoimmunity","volume":"23","author":"Theofilopoulos","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.cyto.2014.11.026_b0100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.0105-2896.2005.00252.x","article-title":"Interferons as pathogenic effectors in autoimmunity","volume":"204","author":"Baccala","year":"2005","journal-title":"Immunol Rev"},{"key":"10.1016\/j.cyto.2014.11.026_b0105","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0952-7915(01)00305-3","article-title":"The interferon-alpha\/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors","volume":"14","author":"Taniguchi","year":"2002","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.cyto.2014.11.026_b0110","doi-asserted-by":"crossref","first-page":"635","DOI":"10.5483\/BMBRep.2004.37.6.635","article-title":"Mechanisms of type-I interferon signal transduction","volume":"37","author":"Uddin","year":"2004","journal-title":"J Biochem Mol Biol"},{"key":"10.1016\/j.cyto.2014.11.026_b0115","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1517\/14740330903066726","article-title":"Type I IFNs and their role in the development of autoimmune diseases","volume":"8","author":"Burdick","year":"2009","journal-title":"Expert Opinion Drug Safety"},{"key":"10.1016\/j.cyto.2014.11.026_b0120","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nrd2422","article-title":"Interferons at age 50: past, current and future impact on biomedicine","volume":"6","author":"Borden","year":"2007","journal-title":"Nat Rev Drug Discovery"},{"key":"10.1016\/j.cyto.2014.11.026_b0125","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/01.mcp.0000134400.88832.9c","article-title":"Interferon-induced granulomatous lung disease","volume":"10","author":"Marzouk","year":"2004","journal-title":"Current Opinion Pulmonary Medicine"},{"key":"10.1016\/j.cyto.2014.11.026_b0130","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1038\/jid.2008.96","article-title":"An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in \u201cinterface dermatitis\u201d","volume":"128","author":"Wenzel","year":"2008","journal-title":"J Invest Dermatol"},{"issue":"37","key":"10.1016\/j.cyto.2014.11.026_b0135","first-page":"659","article-title":"The phenotypic profile of dermatomyositis and lupus erythematosus: a comparative analysis","volume":"2010","author":"Magro","year":"2009","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.cyto.2014.11.026_b0140","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1365-2230.2006.02150.x","article-title":"Interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis","volume":"31","author":"Wenzel","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.cyto.2014.11.026_b0145","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1600-0560.2007.00848.x","article-title":"Plasmacytoid dendritic cells are present in cutaneous dermatomyositis lesions in a pattern distinct from lupus erythematosus","volume":"35","author":"McNiff","year":"2008","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.cyto.2014.11.026_b0150","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/jid.2009.42","article-title":"Lichenoid tissue reaction\/interface dermatitis: clinical and histological perspectives","volume":"129","author":"Sontheimer","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.cyto.2014.11.026_b0155","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","article-title":"Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cyto.2014.11.026_b0160","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1002\/art.22558","article-title":"Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis","volume":"56","author":"Lopez de Padilla","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"302","key":"10.1016\/j.cyto.2014.11.026_b0165","first-page":"113","article-title":"Expression of chemokine receptor CXCR3 by lymphocytes and plasmacytoid dendritic cells in human psoriatic lesions","volume":"2010","author":"Chen","year":"2009","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.cyto.2014.11.026_b0170","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/DAD.0b013e3181a8527f","article-title":"Plasmacytoid (CD68+CD123+) monocytes may play a crucial role in the pathogenesis of hydroa vacciniforme: a case report","volume":"31","author":"Varughese","year":"2009","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.cyto.2014.11.026_b0175","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ana.410160206","article-title":"Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells","volume":"16","author":"Arahata","year":"1984","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cyto.2014.11.026_b0180","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.clim.2010.02.014","article-title":"Human plasmacytoid dendritic cell accumulation amplifies their type 1 interferon production","volume":"136","author":"Liao","year":"2010","journal-title":"Clin Immunol"},{"issue":"29","key":"10.1016\/j.cyto.2014.11.026_b0185","first-page":"273","article-title":"Expression of TLR2, TLR4, and TLR9 in dermatomyositis and polymyositis","volume":"2010","author":"Kim","year":"2009","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.cyto.2014.11.026_b0190","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1212\/WNL.0b013e31821f440a","article-title":"Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies","volume":"76","author":"Cappelletti","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.cyto.2014.11.026_b0195","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1084\/jem.192.2.219","article-title":"Natural interferon alpha\/beta-producing cells link innate and adaptive immunity","volume":"192","author":"Kadowaki","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.cyto.2014.11.026_b0200","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/00002018-199410020-00003","article-title":"Clinical toxicity of the interferons","volume":"10","author":"Vial","year":"1994","journal-title":"Drug Safety: an International Journal of Medical Toxicology and Drug Experience"},{"key":"10.1016\/j.cyto.2014.11.026_b0205","first-page":"498980","article-title":"Targeting Toll-like receptors for treatment of SLE","author":"Horton","year":"2010","journal-title":"Mediat Inflam"},{"key":"10.1016\/j.cyto.2014.11.026_b0210","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/00019052-200406000-00018","article-title":"Uncertainties in the pathogenesis of adult dermatomyositis","volume":"17","author":"Greenberg","year":"2004","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.cyto.2014.11.026_b0215","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ana.21805","article-title":"Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy","volume":"67","author":"Salajegheh","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cyto.2014.11.026_b0220","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.22928","article-title":"Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis","volume":"56","author":"Walsh","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cyto.2014.11.026_b0225","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/BOR.0b013e3282efe261","article-title":"A gene expression approach to study perturbed pathways in myositis","volume":"19","author":"Greenberg","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.cyto.2014.11.026_b0230","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.4049\/jimmunol.168.8.4154","article-title":"Gene expression profiling in DQA1 0501+ children with untreated dermatomyositis: a novel model of pathogenesis","volume":"168","author":"Tezak","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.cyto.2014.11.026_b0235","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-2172-9-43","article-title":"Duration of chronic inflammation alters gene expression in muscle from untreated girls with juvenile dermatomyositis","volume":"9","author":"Chen","year":"2008","journal-title":"BMC Immunol"},{"key":"10.1016\/j.cyto.2014.11.026_b0240","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1002\/art.24936","article-title":"Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis","volume":"60","author":"Bilgic","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cyto.2014.11.026_b0245","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","article-title":"An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity","volume":"13","author":"Baechler","year":"2007","journal-title":"Mol Med"},{"key":"10.1016\/j.cyto.2014.11.026_b0250","doi-asserted-by":"crossref","first-page":"e29161","DOI":"10.1371\/journal.pone.0029161","article-title":"Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases","volume":"7","author":"Wong","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cyto.2014.11.026_b0255","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.22928","article-title":"Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis","volume":"56","author":"Walsh","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cyto.2014.11.026_b0260","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/ard.2010.139949","article-title":"Interferon beta is associated with type 1 interferon-inducible gene expression in dermatomyositis","volume":"70","author":"Liao","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cyto.2014.11.026_b0265","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/S0140-6736(05)79887-1","article-title":"Subacute cutaneous lupus erythematosus associated with interferon beta-1a","volume":"352","author":"Nousari","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.cyto.2014.11.026_b0270","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.immuni.2011.07.012","article-title":"Structure of myxovirus resistance protein a reveals intra- and intermolecular domain interactions required for the antiviral function","volume":"35","author":"Gao","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.cyto.2014.11.026_b0275","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/path.1721","article-title":"Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus","volume":"205","author":"Wenzel","year":"2005","journal-title":"J Pathol"},{"key":"10.1016\/j.cyto.2014.11.026_b0280","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.clim.2006.05.011","article-title":"MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement","volume":"120","author":"O\u2019Connor","year":"2006","journal-title":"Clin Immunol"},{"key":"10.1016\/j.cyto.2014.11.026_b0285","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/path.4346","article-title":"Altered RIG-I\/DDX58-mediated innate immunity in dermatomyositis","volume":"233","author":"Suarez-Calvet","year":"2014","journal-title":"J Pathol"},{"key":"10.1016\/j.cyto.2014.11.026_b0290","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/ni1087","article-title":"The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses","volume":"5","author":"Yoneyama","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1016\/j.cyto.2014.11.026_b0295","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1126\/science.1132505","article-title":"5\u2032-Triphosphate RNA is the ligand for RIG-I","volume":"314","author":"Hornung","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.cyto.2014.11.026_b0300","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1084\/jem.20080091","article-title":"Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5","volume":"205","author":"Kato","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.cyto.2014.11.026_b0305","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/path.4355","article-title":"Sustained autoimmune mechanisms in dermatomyositis","volume":"233","author":"Greenberg","year":"2014","journal-title":"J Pathol"},{"key":"10.1016\/j.cyto.2014.11.026_b0310","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/rheumatology\/kep375","article-title":"The RIG-I-like receptor IFIH1\/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody","volume":"49","author":"Nakashima","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.cyto.2014.11.026_b0315","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/art.24621","article-title":"RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease","volume":"60","author":"Sato","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cyto.2014.11.026_b0320","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/vim.2009.0071","article-title":"Interferon induced with helicase C domain 1 (IFIH1) and virus-induced autoimmunity: a review","volume":"23","author":"Chistiakov","year":"2010","journal-title":"Viral Immunol"},{"key":"10.1016\/j.cyto.2014.11.026_b0325","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1128\/JVI.01690-09","article-title":"Both RIG-I and MDA5 RNA helicases contribute to the induction of alpha\/beta interferon in measles virus-infected human cells","volume":"84","author":"Ikegame","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.cyto.2014.11.026_b0330","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/j.1365-2133.2004.06144.x","article-title":"Infiltrating cells, related cytokines and chemokine receptors in lesional skin of patients with dermatomyositis","volume":"151","author":"Caproni","year":"2004","journal-title":"British J Dermatol"},{"key":"10.1016\/j.cyto.2014.11.026_b0335","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1196\/annals.1398.050","article-title":"Chemokine profile of different inflammatory myopathies reflects humoral versus cytotoxic immune responses","volume":"1109","author":"De Paepe","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.cyto.2014.11.026_b0340","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1365-2990.2004.00591.x","article-title":"Expression of the beta chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies","volume":"31","author":"Civatte","year":"2005","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.cyto.2014.11.026_b0345","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/jnen\/59.2.164","article-title":"Increased expression of beta-chemokines in muscle of patients with inflammatory myopathies","volume":"59","author":"Confalonieri","year":"2000","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.cyto.2014.11.026_b0350","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1212\/WNL.58.12.1779","article-title":"Differential expression of chemokines in inflammatory myopathies","volume":"58","author":"De Bleecker","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.cyto.2014.11.026_b0355","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s004010051041","article-title":"Local expression of monocyte chemoattractant protein-1 (MCP-1) in idiopathic inflammatory myopathies","volume":"97","author":"Liprandi","year":"1999","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.cyto.2014.11.026_b0360","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1600-0404.2010.01353.x","article-title":"Detection of the membrane attack complex as a diagnostic tool in dermatomyositis","volume":"123","author":"Jain","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.cyto.2014.11.026_b0365","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archneur.1991.00530130034016","article-title":"The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis","volume":"48","author":"Kissel","year":"1991","journal-title":"Arch Neurol"},{"key":"10.1016\/j.cyto.2014.11.026_b0370","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJM198602063140601","article-title":"Microvascular deposition of complement membrane attack complex in dermatomyositis","volume":"314","author":"Kissel","year":"1986","journal-title":"New Engl J Med"},{"key":"10.1016\/j.cyto.2014.11.026_b0375","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cyto.2014.11.026_b0380","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/ana.410270402","article-title":"Microvascular changes in early and advanced dermatomyositis: a quantitative study","volume":"27","author":"Emslie-Smith","year":"1990","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cyto.2014.11.026_b0385","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJM198602063140601","article-title":"Microvascular deposition of complement membrane attack complex","volume":"314","author":"Kissel","year":"1986","journal-title":"New Engl J Med"},{"key":"10.1016\/j.cyto.2014.11.026_b0390","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/intimm\/12.9.1329","article-title":"Cytokines and chemokines are both expressed by human myoblasts: possible relevance for the immune pathogenesis of muscle inflammation","volume":"12","author":"De Rossi","year":"2000","journal-title":"Int Immunol"},{"key":"10.1016\/j.cyto.2014.11.026_b0395","first-page":"275","article-title":"The predominance of beta (CC) chemokine transcripts in idiopathic inflammatory muscle diseases","volume":"109","author":"Adams","year":"1997","journal-title":"Proc Assoc Am Physicians"},{"key":"10.1016\/j.cyto.2014.11.026_b0400","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/262302a0","article-title":"Antiviral and cell growth inhibitory activities reside in the same glycoprotein of human fibroblast interferon","volume":"262","author":"Knight","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.cyto.2014.11.026_b0405","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/nm.3268","article-title":"How Cytokine networks fuel inflammation: Interleukin-17 and a tale of two autoimmune diseases","volume":"19","author":"Baeten","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.cyto.2014.11.026_b0410","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/art.11428","article-title":"Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: Interaction with chemokines and Th1 cytokine-producing cells","volume":"50","author":"Page","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cyto.2014.11.026_b0415","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1093\/rheumatology\/keq151","article-title":"Idiopathic inflammatory myopathies, signified by distinctive peripheral cytokines, chemokines and the TNF family members B-cell activating factor and a proliferation inducing ligand","volume":"49","author":"Szodoray","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.cyto.2014.11.026_b0420","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1756-185X.2011.01654.x","article-title":"Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients","volume":"15","author":"Higgs","year":"2012","journal-title":"Int J Rheum Diseases"},{"key":"10.1016\/j.cyto.2014.11.026_b0425","doi-asserted-by":"crossref","first-page":"345347","DOI":"10.1155\/2013\/345347","article-title":"Correlation between the frequency of Th17 cell and the expression of microRNA-206 in patients with dermatomyositis","volume":"2013","author":"Tang","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.cyto.2014.11.026_b0430","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1002\/art.27465","article-title":"Expression of Toll-like receptor 3 and Toll-like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines","volume":"62","author":"Tournadre","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cyto.2014.11.026_b0435","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0165-5728(03)00032-8","article-title":"Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis","volume":"137","author":"Chevrel","year":"2003","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.cyto.2014.11.026_b0440","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jneuroim.2006.03.026","article-title":"IL-6-deficient mice show impaired inflammatory response in a model of myosin-induced experimental myositis","volume":"176","author":"Scuderi","year":"2006","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.cyto.2014.11.026_b0445","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/rheumatology\/kep078","article-title":"Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression","volume":"48","author":"Gunawardena","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.cyto.2014.11.026_b0450","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1002\/art.22860","article-title":"A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52\/anti-Ro 60 autoantibodies","volume":"56","author":"Eloranta","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cyto.2014.11.026_b0455","doi-asserted-by":"crossref","first-page":"290797","DOI":"10.1155\/2014\/290797","article-title":"Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis","volume":"2014","author":"Labrador-Horrillo","year":"2014","journal-title":"J Immunol Res"},{"key":"10.1016\/j.cyto.2014.11.026_b0460","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","article-title":"The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study","volume":"65","author":"Fiorentino","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.cyto.2014.11.026_b0465","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1002\/art.22164","article-title":"A novel autoantibody to a 155-kd protein is associated with dermatomyositis","volume":"54","author":"Targoff","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cyto.2014.11.026_b0470","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1002\/art.38038","article-title":"Interferon-alpha induction and detection of anti-ro, anti-la, anti-sm, and anti-rnp autoantibodies by autoantigen microarray analysis in juvenile dermatomyositis","volume":"65","author":"Balboni","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cyto.2014.11.026_b0475","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/rheumatology\/ket279","article-title":"Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy","volume":"53","author":"Venalis","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.cyto.2014.11.026_b0480","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/annrheumdis-2012-202794","article-title":"A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-alpha monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients","volume":"73","author":"Higgs","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cyto.2014.11.026_b0485","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/rheumatology\/ker152","article-title":"Therapeutic effect of tocilizumab on two patients with polymyositis","volume":"50","author":"Narazaki","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.cyto.2014.11.026_b0490","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1002\/art.24689","article-title":"Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A","volume":"60","author":"Okiyama","year":"2009","journal-title":"Arthritis Rheum"}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466614006097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466614006097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T02:01:21Z","timestamp":1717639281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466614006097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":98,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S1043466614006097"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2014.11.026","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of type I interferons and other cytokines in dermatomyositis","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2014.11.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}